EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH

While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.

Allianz MiCo Milan
The EASL 2024 congress was held at the Allianz MiCo in Milan, Italy. • Source: Shutterstock

More from Clinical Trials

More from R&D